Dr. Ruben Karapetian boasts over 15 years of industrial experience in drug discovery and R&D. He earned his Ph.D. from Moscow State University in 2001 and worked as a guest scientist at the Max-Planck Institute of Molecular Genetics in Berlin. As CSO of AVIonco, he led the development of a successful antiandrogen for castration-resistant prostate cancer, advancing clinical trials to phase I/II.